Expanding the Spectrum of HER2-Positivity for Breast Cancer Care: Implications of HER2-Low Status

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Clinical Care Options, LLC is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. SABCS will base its on-site protocols on the latest guidance from the CDC in addition to local regulations in San Antonio. At this time, the City of San Antonio requires masks indoors in all its public facilities, therefore SABCS will require masks for all in-person attendees. SABCS is not legally able to require vaccinations but recommends everyone that is attending the in-person event be vaccinated. Meeting space will be set to accommodate those attendees who prefer more personal space as well as those who prefer to sit closer together.

SABCS will update this plan, as necessary, in accordance with science and any new guidance issued by federal and state authorities.

Additional information about on-site safety protocols will be posted as it becomes available. We encourage you to visit sabcs.org/2022-SABCS to stay abreast of the latest updates.

The content of the presentations and opinions expressed by presenters are those of the sponsor or presenter and are not of the San Antonio Breast Cancer Symposium®


Welcome, Overview, Audience Polling Questions

  • The Evolving World of HER2 in Advanced Breast Cancer
  • Biomarker Testing and Nuances in HER2-expressing Breast Cancer
  • Available Treatments and Emerging Options for in HER2-Low/Negative Breast Cancer
  • Adverse Event Identification/Management

Audience Question and Answer Session


Date / Time
Event Details


Program Director
Nadia Harbeck, MD, PhD

Head, Breast Center
University of Munich (LMU)
Munich, Germany

Komal Jhaveri, MD

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York

Heather McArthur, MD, MPH

Associate Professor
Department of Medicine
Komen Distinguished Chair in Clinical Breast Cancer
Clinical Director Breast Cancer Program
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, Texas

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to individualize the care of patients with HER2-low status breast cancer.

Target Audience
This program is intended for physicians, pathologists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the science and emerging clinical evidence on HER2 targeted agents in HER2-low breast cancer
  • Outline ways to improve communication and coordination among pathologists, oncologists, and other members of the cancer care team when discussing HER2 test results in patients with breast cancer
  • Plan individualized treatment strategies for patients with HER2-low metastatic breast cancer, considering available clinical evidence and expert recommendations
  • Manage adverse events associated with different HER2 targeted antibody drug conjugates, including procedures to educate patients and optimize quality of life and efficacy of prescribed therapies


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.